HSKA Financial Facts
Other vaccines, pharmaceuticals and products: 7.04MNet income (loss): 3.35M
See Full Income Statement
Cash and cash equivalents: 9.21M
Additional paid-in capital: 236.01M
See Full Balance Sheet
Heska Corp. (HSKA) Earnings
|
Expand Research on HSKA
| Next EPS Date | N/A | EPS Growth Rate | -100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +37.2% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | +5.1% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/7/13 | Q213 | -$0.38 | -$0.01 | -$0.37 | $18.3M | $19.85M | N/A |  | | Details | |
| 5/7/20 |  |
Q120 | -$0.14 | -$0.25 | +$0.11 | $30.7M | $32.66M | = | | | Details |
| 11/5/19 | |
Q319 | -$0.04 | -$0.03 | -$0.01 | $31.2M | $30.34M | N/A | | | Details |
| 8/6/19 | |
Q219 | -$0.03 | -$0.09 | +$0.06 | $28.1M | $28.87M | N/A | | | Details |
11/13/12  |
Q312 | -$0.01 | $0.08 | -$0.09 | $16.9M | $19.7M | N/A | | | Details | |
| 7/27/11 |
|
Q211 | N/A | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | |
| 8/4/20 | |
Q220 | $0.00 | -$0.34 | +$0.34 | $45.7M | $39.89M | = | | | Details |
| 8/8/23 | Q223 | N/A | $0.40 | N/A | N/A | $70.77M | = | N/A | N/A |
